Ethem Turgay Cerit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ethem Turgay Cerit has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Alev Eroglu Altinova
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye
11 shared publications - Mujde Akturk
Gazi University
11 shared publications - Fusun Balos Toruner
Gazi University
10 shared publications - Mehmet Muhittin Yalcin
Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Turkey
10 shared publications - Tugba Barlas
Faculty of Medicine, Department of Endocrinology and Metabolism, Gazi University, Ankara, Turkey
10 shared publications - Ayhan Karakoc
Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye
9 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 9 (5) , 1472-1478
Sleep quality and associated factors of hypothyroid patients: a cross-sectional study
Aims: To evaluate sleep quality and identify sociodemographic and clinical factors associated with sleep quality among patients diagnosed with hypothyroidism.Methods: A descriptive cross-sectional approach was used, with data collected from February 5 through April 6, 2024, at a university hospital’s thyroid outpatient unit. The study enrolled 94 patients with confirmed hypothyroidism. Data were collected using a researcher-designed Patient Identification Form and the Pittsburgh Sleep Quality Index. Statistical evaluation included descriptive analyses, independent-samples t-tests, one-way ANOVA, and multiple linear regression.Results: Participants had a mean age of 51.72±11.18 years, with females comprising 89.4% of the sample. The mean sleep quality score was 7.21±4.77, and 62.8% of participants demonstrated poor sleep quality. Individuals with advanced educational backgrounds exhibited superior sleep quality, whereas those with concurrent health conditions and prior sleep difficulties showed substantially diminished sleep quality. Together, these three variables explained 22.0% of the variance in sleep quality outcomes (R²=0,22; F=8,31; p
- 19 September 2026
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 9 (5) , 1472-1478
Open AccessSleep quality and associated factors of hypothyroid patients: a cross-sectional study
Aims: To evaluate sleep quality and identify sociodemographic and clinical factors associated with sleep quality among patients diagnosed with hypothyroidism.Methods: A descriptive cross-sectional approach was used, with data collected from February 5 through April 6, 2024, at a university hospital’s thyroid outpatient unit. The study enrolled 94 patients with confirmed hypothyroidism. Data were collected using a researcher-designed Patient Identification Form and the Pittsburgh Sleep Quality Index. Statistical evaluation included descriptive analyses, independent-samples t-tests, one-way ANOVA, and multiple linear regression.Results: Participants had a mean age of 51.72±11.18 years, with females comprising 89.4% of the sample. The mean sleep quality score was 7.21±4.77, and 62.8% of participants demonstrated poor sleep quality. Individuals with advanced educational backgrounds exhibited superior sleep quality, whereas those with concurrent health conditions and prior sleep difficulties showed substantially diminished sleep quality. Together, these three variables explained 22.0% of the variance in sleep quality outcomes (R²=0,22; F=8,31; p
- Open Access
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
The Evaluation of the Predictive Value of Early Postoperative Biochemical Parameters for Remission in Patients with Acromegaly
Objective: This study aimed to evaluate the predictive value of growth hormone (GH), insulin-like growth factor-1 (IGF-1), calcium (Ca), and phosphorus (P) levels in the first 2-4 days after surgery for achieving biochemical remission in patients with newly diagnosed acromegaly. Methods: This retrospective cohort study included patients with acromegaly who underwent surgery. Preoperative and early postoperative days 2-4 (POD2-4), 3rd month, and 12th month serum levels of GH, IGF-1, Ca, and P were obtained. Age-normalized IGF-1 levels defined remission at 3-6 months, and patients were grouped accordingly. Results: Biochemical remission was achieved in 44 of 68 patients (64.7%). Preoperative GH, IGF-1, and Ca were significantly higher in the non-remission group (all P < .05), while P did not differ. In POD2-4, all parameters, including P, were significantly higher in the non-remission group (P < .05). Receiver operating characteristic (ROC) analysis showed that a GH ≤1.28 in POD2-4 (AUC = 0.858, sensitivity: 0.74, specificity: 0.88) and a ≥45.29% decrease in IGF-1 from preoperative values (AUC = 0.816; sensitivity: 0.73, specificity: 0.79) predicted remission. At 12 months, GH and IGF-1 remained significantly different, whereas Ca and P did not (P = .67 and P = .20). Conclusion: In patients with acromegaly, GH, IGF-1, Ca, and P levels measured in the first 2-4 days after surgery were found to be significantly lower in the remission group than in those who did not achieve remission. Postoperative GH levels and the percentage decrease in IGF-1 levels were associated with remission and may help with early risk stratification. Cite this article as: Babayeva A, Coskun M, Ozturk O, et al. The evaluation of the predictive value of early postoperative biochemical parameters for remission in patients with acromegaly. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26985
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
Open AccessThe Evaluation of the Predictive Value of Early Postoperative Biochemical Parameters for Remission in Patients with Acromegaly
Objective: This study aimed to evaluate the predictive value of growth hormone (GH), insulin-like growth factor-1 (IGF-1), calcium (Ca), and phosphorus (P) levels in the first 2-4 days after surgery for achieving biochemical remission in patients with newly diagnosed acromegaly. Methods: This retrospective cohort study included patients with acromegaly who underwent surgery. Preoperative and early postoperative days 2-4 (POD2-4), 3rd month, and 12th month serum levels of GH, IGF-1, Ca, and P were obtained. Age-normalized IGF-1 levels defined remission at 3-6 months, and patients were grouped accordingly. Results: Biochemical remission was achieved in 44 of 68 patients (64.7%). Preoperative GH, IGF-1, and Ca were significantly higher in the non-remission group (all P < .05), while P did not differ. In POD2-4, all parameters, including P, were significantly higher in the non-remission group (P < .05). Receiver operating characteristic (ROC) analysis showed that a GH ≤1.28 in POD2-4 (AUC = 0.858, sensitivity: 0.74, specificity: 0.88) and a ≥45.29% decrease in IGF-1 from preoperative values (AUC = 0.816; sensitivity: 0.73, specificity: 0.79) predicted remission. At 12 months, GH and IGF-1 remained significantly different, whereas Ca and P did not (P = .67 and P = .20). Conclusion: In patients with acromegaly, GH, IGF-1, Ca, and P levels measured in the first 2-4 days after surgery were found to be significantly lower in the remission group than in those who did not achieve remission. Postoperative GH levels and the percentage decrease in IGF-1 levels were associated with remission and may help with early risk stratification. Cite this article as: Babayeva A, Coskun M, Ozturk O, et al. The evaluation of the predictive value of early postoperative biochemical parameters for remission in patients with acromegaly. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26985
- Top Cited Papers
- 16 July 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus
Intrapancreatic fat deposition (IPFD) has garnered appreciable attention across diverse medical disciplines amid the rising global burden of pancreatitis, pancreatic cancer and type 2 diabetes mellitus. Despite growing interest in the field, there remains no conceptual framework for it. To address this gap, 25 experts from 6 continents were brought together to develop guidance. Drawing on multiple peer-reviewed systematic reviews and applying an iterative, anonymous Delphi process, a consensus document was developed and ratified in Melbourne, Australia. The final document contains 58 recommendations - 30 reached unanimous agreement and 28 attained 90-99% agreement. The consensus formally defines fatty pancreas disorder (FPD) as a distinct pathological state, characterized by excessive IPFD that poses a risk to health. Assessment of IPFD is best performed with MRI. Expert-established diagnostic criteria enable identification and classification of FPD. Recognition of type 1 FPD (in individuals without excess body fat mass) and type 2 FPD (in individuals with excess body fat mass) is instrumental in gaining novel insights and tailoring preventive strategies to the individual. The Melbourne consensus is foundational in operationalizing the dissemination of new knowledge in the field, fostering intercontinental collaborations and, ultimately, addressing the global burden of diseases of the pancreas.
- 16 July 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
Top Cited PapersConceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus
Intrapancreatic fat deposition (IPFD) has garnered appreciable attention across diverse medical disciplines amid the rising global burden of pancreatitis, pancreatic cancer and type 2 diabetes mellitus. Despite growing interest in the field, there remains no conceptual framework for it. To address this gap, 25 experts from 6 continents were brought together to develop guidance. Drawing on multiple peer-reviewed systematic reviews and applying an iterative, anonymous Delphi process, a consensus document was developed and ratified in Melbourne, Australia. The final document contains 58 recommendations - 30 reached unanimous agreement and 28 attained 90-99% agreement. The consensus formally defines fatty pancreas disorder (FPD) as a distinct pathological state, characterized by excessive IPFD that poses a risk to health. Assessment of IPFD is best performed with MRI. Expert-established diagnostic criteria enable identification and classification of FPD. Recognition of type 1 FPD (in individuals without excess body fat mass) and type 2 FPD (in individuals with excess body fat mass) is instrumental in gaining novel insights and tailoring preventive strategies to the individual. The Melbourne consensus is foundational in operationalizing the dissemination of new knowledge in the field, fostering intercontinental collaborations and, ultimately, addressing the global burden of diseases of the pancreas.
- Open Access
- 24 April 2026
- Published by S. Karger AG in Obesity Facts
- p. 1-23
Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study
Background: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.
- 24 April 2026
- Published by S. Karger AG in Obesity Facts
- p. 1-23
Open AccessReal-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study
Background: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.
- Open Access
- 23 February 2026
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 19
Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystem disorder characterized by hepatic lipid accumulation, low-grade inflammation, and metabolic dysregulation. Although the kynurenine pathway has been implicated in the pathogenesis of metabolic and inflammatory diseases, its contribution to MASLD remains unclear. This study aimed to evaluate tryptophan (TRP) metabolism and its relationship with inflammatory biomarkers and lipid parameters across different grades of steatosis. A total of 88 adults (62 MASLD, 26 healthy controls; aged 20-69 years) were enrolled in this study. Serum concentrations of inflammatory markers (CRP, IL-6, and TNF-α) were determined using immunoassay-based methods, and TRP metabolites (TRP, KYN, KYNA, 3-HK, 3-HAA, QA, PIC) were quantified using validated LC–MS/MS. Steatosis grades (0-3) were assessed via ultrasonography. Statistical analyses included the Mann–Whitney U test, the Kruskal–Wallis test, and the Spearman correlation test. MASLD subjects showed significantly higher BMI, triglycerides, AST, ALT, GGT, CRP, TNF-α, and KYNA levels compared with controls (all P < .05), while HDL-C levels were lower ( P = .014). Across steatosis grades, BMI, TG, and CRP increased progressively ( P < .001), and IL-6 showed a positive correlation with steatosis severity ( r = .280, P < .05). KYNA levels were elevated in early steatosis (Grade 1, P = .008) and inversely correlated with TC and LDL-C ( r = −.393 and r = −.384, respectively). The elevation of KYNA may reflect an early compensatory mechanism imitigating hepatic and metabolic stress. Integrating inflammatory and kynurenine pathway biomarkers could improve disease stratification and therapeutic targeting in MASLD.
- 23 February 2026
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 19
Open AccessAltered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystem disorder characterized by hepatic lipid accumulation, low-grade inflammation, and metabolic dysregulation. Although the kynurenine pathway has been implicated in the pathogenesis of metabolic and inflammatory diseases, its contribution to MASLD remains unclear. This study aimed to evaluate tryptophan (TRP) metabolism and its relationship with inflammatory biomarkers and lipid parameters across different grades of steatosis. A total of 88 adults (62 MASLD, 26 healthy controls; aged 20-69 years) were enrolled in this study. Serum concentrations of inflammatory markers (CRP, IL-6, and TNF-α) were determined using immunoassay-based methods, and TRP metabolites (TRP, KYN, KYNA, 3-HK, 3-HAA, QA, PIC) were quantified using validated LC–MS/MS. Steatosis grades (0-3) were assessed via ultrasonography. Statistical analyses included the Mann–Whitney U test, the Kruskal–Wallis test, and the Spearman correlation test. MASLD subjects showed significantly higher BMI, triglycerides, AST, ALT, GGT, CRP, TNF-α, and KYNA levels compared with controls (all P < .05), while HDL-C levels were lower ( P = .014). Across steatosis grades, BMI, TG, and CRP increased progressively ( P < .001), and IL-6 showed a positive correlation with steatosis severity ( r = .280, P < .05). KYNA levels were elevated in early steatosis (Grade 1, P = .008) and inversely correlated with TC and LDL-C ( r = −.393 and r = −.384, respectively). The elevation of KYNA may reflect an early compensatory mechanism imitigating hepatic and metabolic stress. Integrating inflammatory and kynurenine pathway biomarkers could improve disease stratification and therapeutic targeting in MASLD.
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1) , 20261556
Serum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia
Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments. Methods: In this cross-sectional study, male and female adults were stratified into three groups: dysglycaemic individuals with MASLD (MASLD-Dys), dysglycaemic individuals without MASLD (Dys), and normoglycaemic individuals without MASLD as healthy controls. Imaging-based hepatic fat quantification, body composition, anthropometric and biochemical parameters, and non-invasive indices assessing hepatic steatosis and fibrosis were evaluated. Results: Compared with Dys participants, MASLD-Dys participants had higher body mass index (BMI), waist circumference, trunk fat mass, ultrasound-derived hepatic fat fraction (USFF), and Fatty Liver Index (FLI). The strongest between-group separation was observed for USFF (p<0.001). In receiver operating characteristic analysis, USFF showed the highest discriminative performance for MASLD-Dys vs. Dys, with an area under the curve of 0.925 and an optimal cut-off of ≥6.95 %. Conclusions: USFF was the strongest discriminator of MASLD among dysglycaemic adults, while FLI provided a practical non-imaging alternative. These findings support integrating hepatic fat quantification and body composition measures into MASLD risk stratification beyond glycaemic status alone.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1) , 20261556
Open AccessSerum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia
Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments. Methods: In this cross-sectional study, male and female adults were stratified into three groups: dysglycaemic individuals with MASLD (MASLD-Dys), dysglycaemic individuals without MASLD (Dys), and normoglycaemic individuals without MASLD as healthy controls. Imaging-based hepatic fat quantification, body composition, anthropometric and biochemical parameters, and non-invasive indices assessing hepatic steatosis and fibrosis were evaluated. Results: Compared with Dys participants, MASLD-Dys participants had higher body mass index (BMI), waist circumference, trunk fat mass, ultrasound-derived hepatic fat fraction (USFF), and Fatty Liver Index (FLI). The strongest between-group separation was observed for USFF (p<0.001). In receiver operating characteristic analysis, USFF showed the highest discriminative performance for MASLD-Dys vs. Dys, with an area under the curve of 0.925 and an optimal cut-off of ≥6.95 %. Conclusions: USFF was the strongest discriminator of MASLD among dysglycaemic adults, while FLI provided a practical non-imaging alternative. These findings support integrating hepatic fat quantification and body composition measures into MASLD risk stratification beyond glycaemic status alone.
- Open Access
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1602-1612
Endocrine disruptors, obesity, and metabolic syndrome
The global prevalence of obesity and metabolic syndrome (MetS) is rising worldwide, and increasing evidence suggests that chemical exposures—particularly endocrine disruptors (EDs)—represent a significant contributing factor. EDs can act as obesogens, increasing the risk of weight gain and related metabolic conditions, including type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. They may also alter the basal metabolic rate, gut microbiota composition, and hormonal regulation of appetite and satiety. EDs are reported to exert their effects mainly through the peroxisome proliferator-activated receptor gamma pathway, which is primarily expressed in adipose tissue and is a key regulator of adipogenesis. Common consumer products such as plastic bottles, metal food cans, detergents, toys, cosmetics, and pesticides frequently contain EDs. Humans can be exposed to these chemicals via multiple routes, including transplacental transfer, breast milk, inhalation, ingestion, and dermal absorption. Bisphenols, tributyltin, phthalates, per- and polyfluoroalkyl substances, polycyclic aromatic hydrocarbons, and heavy metals are among the known EDs that have been associated with obesity and MetS. The need for further investigation and stricter regulations to mitigate the public health consequences of environmental exposure to EDs is consistently emphasized in recent literature. Understanding the mechanisms by which EDs affect various hormones and systems is essential for developing effective prevention and intervention strategies. In this review, we discuss the relationship between obesity, MetS, and EDs, along with exposure pathways and preventive strategies.
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1602-1612
Open AccessEndocrine disruptors, obesity, and metabolic syndrome
The global prevalence of obesity and metabolic syndrome (MetS) is rising worldwide, and increasing evidence suggests that chemical exposures—particularly endocrine disruptors (EDs)—represent a significant contributing factor. EDs can act as obesogens, increasing the risk of weight gain and related metabolic conditions, including type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. They may also alter the basal metabolic rate, gut microbiota composition, and hormonal regulation of appetite and satiety. EDs are reported to exert their effects mainly through the peroxisome proliferator-activated receptor gamma pathway, which is primarily expressed in adipose tissue and is a key regulator of adipogenesis. Common consumer products such as plastic bottles, metal food cans, detergents, toys, cosmetics, and pesticides frequently contain EDs. Humans can be exposed to these chemicals via multiple routes, including transplacental transfer, breast milk, inhalation, ingestion, and dermal absorption. Bisphenols, tributyltin, phthalates, per- and polyfluoroalkyl substances, polycyclic aromatic hydrocarbons, and heavy metals are among the known EDs that have been associated with obesity and MetS. The need for further investigation and stricter regulations to mitigate the public health consequences of environmental exposure to EDs is consistently emphasized in recent literature. Understanding the mechanisms by which EDs affect various hormones and systems is essential for developing effective prevention and intervention strategies. In this review, we discuss the relationship between obesity, MetS, and EDs, along with exposure pathways and preventive strategies.
- Open Access
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1595-1601
Endocrine disruptors, insulin resistance, and diabetes
Endocrine-disrupting chemicals (EDCs) are compounds that interfere with hormone synthesis, secretion, metabolism, or excretion. Evidence indicates that increased exposure to EDCs is associated with insulin resistance and, most notably, type 2 diabetes worldwide. This suggests a diabetogenic effect that is independent of obesity, underscoring the complex mechanisms and broad impact of EDCs on metabolic health. Key pathways include hormone mimicry and antagonism, altered hormone metabolism, inflammatory responses, and mitochondrial dysfunction. This review summarises the mechanisms through which EDCs contribute to these conditions and evaluates the epidemiological and experimental evidence supporting these associations.
- 17 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (7) , 1595-1601
Open AccessEndocrine disruptors, insulin resistance, and diabetes
Endocrine-disrupting chemicals (EDCs) are compounds that interfere with hormone synthesis, secretion, metabolism, or excretion. Evidence indicates that increased exposure to EDCs is associated with insulin resistance and, most notably, type 2 diabetes worldwide. This suggests a diabetogenic effect that is independent of obesity, underscoring the complex mechanisms and broad impact of EDCs on metabolic health. Key pathways include hormone mimicry and antagonism, altered hormone metabolism, inflammatory responses, and mitochondrial dysfunction. This review summarises the mechanisms through which EDCs contribute to these conditions and evaluates the epidemiological and experimental evidence supporting these associations.